Raav2tyf-cb-hrs1
WebSafety and Biodistribution Evaluation in Cynomolgus Macaques of rAAV2tYF-CB-hRS1, a Recombinant Adeno-Associated Virus Vector Expressing Retinoschisin. Hum Gene Ther Clin Dev. Sep;26(3):165-76. PMID: 26390090; AAV2(Y-F+T-V)
Raav2tyf-cb-hrs1
Did you know?
WebrAAV2tYF-CB-hRS1 administered by intravitreal injection in one eye in individuals with XLRS. The primary objective is to evaluate safety and the secondary objective is to evaluate efficacy. Each participant is to receive rAAV2tYF-CB-hRS1 by intravitreal injection in one eye on a single occasion as outlined in the schematic below. WebSummary. This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector expressing retinoschisin (rAAV2tYF-CB-hRS1) in patients with X …
WebDec 14, 2024 · The phase 1/2 study investigated rAAV2tYF-CB-hRS1 in patients with XLRS due to mutations in the RS1 gene which provides instructions for the production of the protein called retinoschisin and is found in the retina. After six months of treatment, the drug was generally safe and well-tolerated but did not show any signs of clinical activity. WebApr 13, 2024 · Applied Genetic discontinued its XLRS clinical program and development of rAAV2tYF-CB-hRS1 in 2024 because defined efficacy endpoints were not met using intravitreal injection.
WebMay 1, 2015 · rAAV2tYF-CB-hRS1 in Nonhuman Primates Guo-jie Y e, 1 Ewa Budzynski, 2 Peter Sonnentag, 2 Paul Miller, 3 Alok K. Sharma, 2 James Hoeve, 3 Kenneth S. Latimer, 2 Kellie Howard, 4 WebMar 30, 2024 · In XLRS mouse, AAV2/2-Y444F–mediated mCherry expression is restricted to cells in the inner retina.Retinal expression of fluorescent transgenes mCherry was examined 5 weeks after intravitreal injection of In4s-In3-200En-mGluR500P-mCherry (mini-mGluR6-mCherry) into XLRS mouse retina. mCherry expression was restricted to cells in the inner …
WebMar 1, 2024 · Recently, an instructive paper was published detailing the 12-month results from intravitreal injections of AAV (rAAV2tYF-CB-hRS1) for patients with X-linked retinoschisis. 5 Therein, the authors highlight that their gene augmentation strategy did not demonstrate a measurable improvement for patients as investigated with visual acuity, …
WebPurpose: To evaluate the safety and efficacy of rAAV2tYF-CB-hRS1, a recombinant adeno-associated virus vector expressing retinoschisin (RS1), in individuals with retinal disease … takeuchi bordeauxWebAug 25, 2015 · We report here results of a study evaluating the safety and biodistribution of rAAV2tYF-CB-hRS1 in RS1-deficient mice. Three groups of male RS1-deficient mice received an intravitreal injection in one eye of either vehicle, or rAAV2tYF-CB-hRS1 at one of two dose levels (1 × 10 9 or 4 × 10 9 vg/eye) and were sacrificed 30 or 90 days later. twitch optlolWebMay 10, 2024 · 25. Ye GJ, Budzynski E, Sonnentag P, Miller PE, Sharma AK, Ver Hoeve JN, Howard K, Knop DR, Neuringer M, McGill T et al. Safety and biodistribution evaluation in cynomolgus macaques of rAAV2tYF-CB-hRS1, a recombinant adeno-associated virus vector expressing retinoschisin. Hum Gene Ther Clin Dev 2015;26:3:165-176. 26. takeuchi brand compact excavatorsWebSecondary: To evaluate the efficacy of rAAV2tYF-CB-hRS1 in patients with X-linked retinoschisis Study Design: This will be a non-randomized, open label, Phase 1/2 dose … twitch opt outWebDec 1, 2024 · The rAAV2tYF-CB-hRS1 trial remains ongoing through 5 years of follow-up to assess long-term safety, and insights gained from the initial treatment and 12-month … takeuchi brush cutterWebMar 4, 2024 · March 4, 2024. Biogen has agreed to acquire Nightstar Therapeutics for approximately $877 million, the companies said today, in a deal that replenishes the buyer’s ophthalmology drug pipeline ... takeuchi charlotteWebMay 1, 2015 · Histological examination showed mononuclear cell infiltrates that were more prevalent at the higher dose level and RS1 expression in the retinal ganglion cell ring was … twitch opiniones